12.12
+3.32%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AngioDynamics
From its filings with the US Securities and Exchange Commission
AngioDynamics is based in Latham, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ANGO. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 May 2026, it reported revenue of $320.2m and a net loss of $36.7m. At that date it held total assets of $267.2m and shareholders' equity of $170.8m.
AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance.
AngioDynamics was founded in Queensbury, N.Y., U.S., in 1988 and began manufacturing and shipping product in the early 1990s. The Company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury facility. Initially dedicated to the research and development of products used in interventional radiology, the Company soon became well established as a producer of diagnostic catheters for non-coronary angiography and thrombolytic delivery systems.
The Company grew over the following years as a result of acquisitions of companies including RITA Medical Systems in January 2007, Oncobionic in May 2008, the assets of Diomed in June 2008, Vortex Medical, Inc. in October 2012, the assets of Microsulis Medical Limited in January 2013, and Clinical Devices in August 2013. These acquisitions added product lines including ablation and NanoKnife systems, vascular access products, angiographic products and accessories, dialysis products, drainage products, thrombolytic products, embolization products and venous products.
Quoted from its 10-K, filed 14 Jul 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 27 May 2004
- Employees
- 632
- Website
- angiodynamics.com ↗
- Head office
- 14 PLAZA DRIVE, LATHAM, NY, 12110
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Howard DonnellyIndependent Non-Executive Chairman of the Board$268,525
- Mr. James ClemmerPresident, Chief Executive Officer, Director, since 2016$5.5m
- Mr. Stephen TrowbridgeChief Financial Officer, Executive Vice President$2.2m
- Mr. Chad CampbellSenior Vice President, General Manager - Global Oncology and Vascular Access$1.0m
- Ms. Laura PiccininiSenior Vice President, General Manager - Endovascular Therapies and International$1.4m
- Mr. Lawrence WeissSenior Vice President, Chief Legal Officer and Corporate Secretary$1.2m
- Mr. Warren NighanSenior Vice President - Global Supply Chain, Quality and Regulatory Affairs$1.2m
- Ms. Eileen AuenIndependent Director$238,525
- Ms. Lorinda BurgessIndependent Director$231,025
- Mr. Wesley JohnsonIndependent Director$246,025
- Ms. Karen LicitraIndependent Director$231,025
- Ms. Jan ReedIndependent Director$241,025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 38
- Environment
- 8
- Social
- 39
- Governance
- 68
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong market presence: AngioDynamics Inc has established a strong presence in the medical device industry, particularly in the field of minimally invasive therapeutic and diagnostic technologies.
- Diverse product portfolio: The company offers a wide range of innovative medical devices, including vascular access products, vascular interventions, angiographic products, and oncology systems, which cater to various healthcare needs.
- Technological advancements: AngioDynamics Inc invests heavily in research and development to ensure continuous innovation and technological advancements in its products, enabling it to stay ahead of competitors.
- Strong financial position: The company has demonstrated strong financial performance, with steady revenue growth and healthy profit margins, providing a solid foundation for future investments and expansion.
Weaknesses
- Dependence on a limited customer base: AngioDynamics Inc heavily relies on a few key customers, which can pose a risk if any of them significantly reduce or terminate their business relationships with the company.
- Regulatory challenges: The medical device industry is subject to strict regulations and compliance requirements, and any non-compliance can result in product delays or recalls, impacting the company's reputation and financial performance.
- Limited global presence: While the company has a solid market presence in the United States, its international market penetration is relatively limited, which restricts its growth potential in global markets.
- Intense competition: AngioDynamics Inc faces intense competition from both established medical device companies and emerging startups, which may result in price pressure and difficulty in maintaining market share.
Opportunities
- Growing demand for minimally invasive procedures: There is an increasing trend towards minimally invasive surgeries and treatments, presenting an opportunity for AngioDynamics Inc to expand its market share in this rapidly growing segment.
- Expansion into emerging markets: The company can capitalize on the growing healthcare infrastructure in emerging markets by expanding its global presence and partnering with local distributors or healthcare providers.
- Strategic collaborations and acquisitions: AngioDynamics Inc can explore strategic collaborations or acquisitions to enhance its product portfolio, gain access to new technologies, and expand its customer base.
- Focus on oncology market: The rising prevalence of cancer and increasing adoption of minimally invasive treatments in oncology create opportunities for the company to develop specialized products and solutions catering to this market segment.
Threats
- Economic downturns: Any economic downturn or financial crisis can impact healthcare spending, leading to a decrease in demand for medical devices and potentially affecting AngioDynamics Inc's sales and revenue.
- Stringent regulatory environment: The medical device industry is subject to evolving and complex regulations, and compliance failures can lead to penalties, product recalls, or a halt in manufacturing, which may affect the company's operations and financial performance.
- Price pressure from competitors: Intense competition within the industry can result in price wars and reduced profit margins, especially if competitors offer similar products at lower prices, posing a threat to AngioDynamics Inc's market position.
- Technological obsolescence: Rapid advancements in technology and medical innovations could render existing products obsolete, necessitating continuous investments in research and development to stay ahead of market trends.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.